Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease

J Clin Gastroenterol. 2013 Feb;47(2):139-47. doi: 10.1097/MCG.0b013e31827759ac.


Background/aims: The aim of this exploratory trial was to establish if the probiotic Bifidobacterium natren life start (NLS) strain strain may affect the clinical course and pathophysiological features of patients with untreated celiac disease (CD). Positive findings would be helpful in directing future studies.

Methods: Twenty-two adult patients having 2 positives CD-specific tests were enrolled. Patients were randomized to receive 2 capsules before meals for 3 weeks of either Bifidobacterium infantis natren life start strain super strain (Lifestart 2) (2×10(9) colony-forming units per capsule) (n = 12) or placebo (n = 10), whereas they also consumed at least 12 g of gluten/day. A biopsy at the end of the trial confirmed CD in all cases. The primary outcome was intestinal permeability changes. Secondary endpoints were changes in symptoms and the Gastrointestinal Symptom Rating Scale, and in immunologic indicators of inflammation.

Results: The abnormal baseline intestinal permeability was not significantly affected by either treatment. In contrast to patients on placebo, those randomized to B. infantis experienced a significant improvement in Gastrointestinal Symptom Rating Scale (P = 0.0035 for indigestion; P = 0.0483 for constipation; P = 0.0586 for reflux). Final/baseline IgA tTG and IgA DGP antibody concentration ratios were lower in the B. infantis arm (P = 0.055 for IgA tTG and P = 0.181 for IgA DGP). Final serum macrophage inflammatory protein-1β increased significantly (P < 0.04) only in patients receiving B. infantis. The administration of B. infantis was safe.

Conclusions: The study suggests that B. infantis may alleviate symptoms in untreated CD. The probiotic produced some immunologic changes but did not modify abnormal intestinal permeability. Further studies are necessary to confirm and/or expand these observations.

Trial registration: ClinicalTrials.gov NCT01257620.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Argentina
  • Autoantibodies / blood
  • Bifidobacterium / growth & development*
  • Biomarkers / blood
  • Biopsy
  • Celiac Disease / blood
  • Celiac Disease / complications
  • Celiac Disease / diagnosis
  • Celiac Disease / immunology
  • Celiac Disease / microbiology
  • Celiac Disease / therapy*
  • Cells, Cultured
  • Chemokine CCL4 / blood
  • Combined Modality Therapy
  • Diet, Gluten-Free
  • Double-Blind Method
  • Female
  • GTP-Binding Proteins
  • Gliadin / immunology
  • Humans
  • Intestinal Absorption
  • Intestinal Mucosa / metabolism
  • Intestines / immunology
  • Intestines / microbiology*
  • Intestines / pathology
  • Lactulose / urine
  • Male
  • Mannitol / urine
  • Middle Aged
  • Peptide Fragments / immunology
  • Permeability
  • Probiotics / therapeutic use*
  • Protein Glutamine gamma Glutamyltransferase 2
  • Surveys and Questionnaires
  • Time Factors
  • Transglutaminases / immunology
  • Treatment Outcome
  • Young Adult


  • Autoantibodies
  • Biomarkers
  • CCL4 protein, human
  • Chemokine CCL4
  • Peptide Fragments
  • Mannitol
  • Lactulose
  • Gliadin
  • Protein Glutamine gamma Glutamyltransferase 2
  • Transglutaminases
  • GTP-Binding Proteins

Associated data

  • ClinicalTrials.gov/NCT01257620